Treatment News : PrEP Adherence Curbs HIV Transmission in Straight Couples

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » September 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


September 16, 2013

PrEP Adherence Curbs HIV Transmission in Straight Couples

HIV-negative heterosexuals who adhere closely to pre-exposure prophylaxis (PrEP) therapy succeed in preventing transmission of the virus from an HIV-positive partner with whom they are in a stable relationship. Publishing their findings in PLOS Medicine, researchers studied 1,147 HIV-negative participants drawn from the three Ugandan sites of the Partners PrEP Study, which gives participants either Viread (tenofovir) or Truvada (tenofovir/emtricitabine) in order to prevent the acquisition of HIV.

The participants were selected for the study because they had at least six months of follow-up remaining in the Partners trial. The group had a median age of 34, was 53 percent male and had an average relationship length of 8.5 years.

The researchers tracked adherence to PrEP through electronic pill bottle monitoring and through unannounced home visits to count pills. If participants’ adherence dropped below 80 percent, they received counseling to support their proper adherence.

Past research has shown that the daily regimen of PrEP decreases in efficacy when it is not taken properly.

Adherence was nearly perfect in the study, with an average of 99 percent in the unannounced home pill counts and 97 percent in the electronic monitoring.  

Out of 404 participants receiving a placebo, who between them contributed 333 person-years of follow-up, 14 contracted HIV. Of the 750 participants receiving PrEP, who contributed 750 person-years of follow-up, none became infected.

“Our study shows that PrEP can be extremely effective in preventing HIV infection when adherence to daily dosing is high,” the paper’s lead author, Jessica Haberer, MD, MS, of the Center for Global Health at Massachusetts General Hospital at Harvard Medical School, said in a release. “Previous studies of PrEP have found considerable variance in efficacy, ranging from as high as 75 percent to no effect at all. We think that the different levels of adherence in those trials explain the differences in their findings, a hypothesis supported by this new study.”

The study was limited by the fact that its participants were not randomized.   

To read the study, click here.

To read a release about the study, click here.

Search: HIV, pre-exposure prophylaxis, PrEP, Viread, tenofovir, Truvada, emticitabine, adherence, electronic pill bottle monitoring, Jessica Haberer, Harvard Medical School, Partners PrEP Study.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.